{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T04:40:43Z","timestamp":1793421643837,"version":"4.5.0"},"reference-count":52,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,10,17]],"date-time":"2023-10-17T00:00:00Z","timestamp":1697500800000},"content-version":"am","delay-in-days":320,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000034","name":"CIHR INMHA","doi-asserted-by":"publisher","award":["FDN-154294"],"award-info":[{"award-number":["FDN-154294"]}],"id":[{"id":"10.13039\/501100000034","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["DA043526"],"award-info":[{"award-number":["DA043526"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001804","name":"Canada Research Chairs","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001804","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010266","name":"Rat f\u00fcr Forschung und Technologieentwicklung","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100010266","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010523","name":"Centre for Addiction and Mental Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010523","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuropharmacology"],"published-print":{"date-parts":[[2022,12]]},"DOI":"10.1016\/j.neuropharm.2022.109291","type":"journal-article","created":{"date-parts":[[2022,10,12]],"date-time":"2022-10-12T05:42:31Z","timestamp":1665553351000},"page":"109291","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["CYP2D in the brain impacts oral hydrocodone analgesia in vivo"],"prefix":"10.1016","volume":"221","author":[{"given":"Janielle","family":"Richards","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharon","family":"Miksys","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Novalen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel F.","family":"Tyndale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.neuropharm.2022.109291_bib1","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpain.2013.01.636","article-title":"Nicotine effect on the efficacy of hydrocodone and oxycodone in chronic pain patients","volume":"14","author":"Ackerman","year":"2013","journal-title":"J. Pain"},{"key":"10.1016\/j.neuropharm.2022.109291_bib2","doi-asserted-by":"crossref","first-page":"6540","DOI":"10.1007\/s12035-021-02560-1","article-title":"Sex and estrous cycle differences in analgesia and brain oxycodone levels","volume":"58","author":"Arguelles","year":"2021","journal-title":"Mol. Neurobiol."},{"key":"10.1016\/j.neuropharm.2022.109291_bib3","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2022.114949","article-title":"Sex, estrous cycle, and hormone regulation of CYP2D in the brain alters oxycodone metabolism and analgesia","author":"Arguelles","year":"2022","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.neuropharm.2022.109291_bib4","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1093\/jat\/bku051","article-title":"Urinary hydrocodone and metabolite distributions in pain patients","volume":"38","author":"Barakat","year":"2014","journal-title":"J. Anal. Toxicol."},{"key":"10.1016\/j.neuropharm.2022.109291_bib5","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1002\/jps.20327","article-title":"Oxycodone pharmacokinetics and pharmacodynamics in the rat in the presence of the P-glycoprotein inhibitor PSC833","volume":"94","author":"Bostr\u00f6m","year":"2005","journal-title":"J Pharm Sci"},{"key":"10.1016\/j.neuropharm.2022.109291_bib6","doi-asserted-by":"crossref","first-page":"2448","DOI":"10.1001\/jama.2018.18472","article-title":"Opioids for chronic noncancer pain: a systematic review and meta-analysis","volume":"320","author":"Busse","year":"2018","journal-title":"JAMA"},{"key":"10.1016\/j.neuropharm.2022.109291_bib7","series-title":"StatPearls [Internet]","article-title":"Hydrocodone","author":"Cofano","year":"2021"},{"key":"10.1016\/j.neuropharm.2022.109291_bib8","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1097\/00002508-200305000-00005","article-title":"Sex differences in opioid analgesia: \"from mouse to man","volume":"19","author":"Craft","year":"2003","journal-title":"Clin. J. Pain"},{"key":"10.1016\/j.neuropharm.2022.109291_bib9","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1002\/cpt.2149","article-title":"Clinical pharmacogenetics implementation consortium guideline for CYP2D6, OPRM1, and COMT genotypes and select opioid therapy","volume":"110","author":"Crews","year":"2021","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.neuropharm.2022.109291_bib10","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.15585\/mmwr.mm6736a2","article-title":"Prevalence of chronic pain and high-impact chronic pain among adults- United States,2016","volume":"67","author":"Dahlhamer","year":"2018","journal-title":"MMWR Morb. Mortal. Wkly. Rep."},{"key":"10.1016\/j.neuropharm.2022.109291_bib11","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.1001\/jama.2016.1464","article-title":"CDC guideline for prescribing opioids for chronic pain--United States, 2016","volume":"315","author":"Dowell","year":"2016","journal-title":"JAMA"},{"key":"10.1016\/j.neuropharm.2022.109291_bib12","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1124\/dmd.31.3.282","article-title":"Induction of cytochrome P450 enzymes in cultured precision-cut human liver slices","volume":"31","author":"Edwards","year":"2003","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.neuropharm.2022.109291_bib13","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/0014-2999(79)90201-2","article-title":"Brain distribution of propranolol in the rat","volume":"55","author":"Elghozi","year":"1979","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2022.109291_bib14","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1007\/s002100000266","article-title":"Affinity, potency and efficacy of tramadol and its metabolites at the cloned human mu-opioid receptor","volume":"362","author":"Gillen","year":"2000","journal-title":"Naunyn-Schmiedeberg\u2019s Arch. Pharmacol."},{"key":"10.1016\/j.neuropharm.2022.109291_bib15","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1046\/j.1365-2125.2003.02002.x","article-title":"CYP2D6 and CYP3A4 involvement in the primary oxidative metabolism of hydrocodone by human liver microsomes","volume":"57","author":"Hutchinson","year":"2004","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.neuropharm.2022.109291_bib16","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.tips.2004.02.007","article-title":"Pharmacogenetics of cytochrome P450 and its applications in drug therapy: the past, present and future","volume":"25","author":"Ingelman-Sundberg","year":"2004","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.neuropharm.2022.109291_bib17","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/0006-8993(86)91138-8","article-title":"Comparison of the antinociceptive action of mu and delta opioid receptor ligands in the periaqueductal gray matter, medial and paramedial ventral medulla in the rat as studied by the microinjection technique","volume":"372","author":"Jensen","year":"1986","journal-title":"Brain Res."},{"key":"10.1016\/j.neuropharm.2022.109291_bib18","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1038\/jes.2010.7","article-title":"Determinants of serum cotinine and hair cotinine as biomarkers of childhood secondhand smoke exposure","volume":"20","author":"Kalkbrenner","year":"2010","journal-title":"J. Expo. Sci. Environ. Epidemiol."},{"key":"10.1016\/j.neuropharm.2022.109291_bib19","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/S0022-3565(24)36599-1","article-title":"Inhibition of cytochrome P450 2D6 metabolism of hydrocodone to hydromorphone does not importantly affect Abuse liability","volume":"281","author":"Kaplan","year":"1997","journal-title":"J. Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.neuropharm.2022.109291_bib20","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/S0031-6997(24)01514-X","article-title":"Animal models of nociception","volume":"53","author":"Le Bars","year":"2001","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.neuropharm.2022.109291_bib21","doi-asserted-by":"crossref","first-page":"390","DOI":"10.3109\/00498254.2012.715697","article-title":"Update on hydrocodone metabolites in rats and dogs aided with a semi-automatic software for metabolite identification Mass-MetaSite","volume":"43","author":"Li","year":"2013","journal-title":"Xenobiotica"},{"key":"10.1016\/j.neuropharm.2022.109291_bib22","doi-asserted-by":"crossref","first-page":"2160","DOI":"10.1016\/j.neurobiolaging.2011.08.014","article-title":"The neuroprotective enzyme CYP2D6 increases in the brain with age and is lower in Parkinson's disease patients","volume":"33","author":"Mann","year":"2012","journal-title":"Neurobiol. Aging"},{"key":"10.1016\/j.neuropharm.2022.109291_bib49","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1016\/j.neuropharm.2008.07.017","article-title":"Induction of the drug metabolizing enzyme CYP2D in monkey brain by chronic nicotine treatment","volume":"55","author":"Mann","year":"2008","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2022.109291_bib23","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/j.brainresbull.2020.09.001","article-title":"Centrally administered CYP2D inhibitors increase oral tramadol analgesia in rats","volume":"164","author":"McMillan","year":"2020","journal-title":"Brain Res. Bull."},{"key":"10.1016\/j.neuropharm.2022.109291_bib24","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1111\/adb.12590","article-title":"Rat brain CYP2D activity alters in vivo central oxycodone metabolism, levels and resulting analgesia","volume":"24","author":"McMillan","year":"2019","journal-title":"Addiction Biol."},{"key":"10.1016\/j.neuropharm.2022.109291_bib52","doi-asserted-by":"crossref","first-page":"1804","DOI":"10.1038\/npp.2015.32","article-title":"Nicotine Increases Codeine Analgesia Through the Induction of Brain CYP2D and Central Activation of Codeine to Morphine","volume":"40","author":"McMillan","year":"2015","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.neuropharm.2022.109291_bib25","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.bcp.2017.08.015","article-title":"Inducing rat brain CYP2D with nicotine increases the rate of codeine tolerance; predicting the rate of tolerance from acute analgesic response","volume":"145","author":"McMillan","year":"2017","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.neuropharm.2022.109291_bib26","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.2174\/156802611795371288","article-title":"Opioid analgesics and P-glycoprotein efflux transporters: a potential systems-level contribution to analgesic tolerance","volume":"11","author":"Mercer","year":"2011","journal-title":"Curr. Top. Med. Chem."},{"key":"10.1016\/j.neuropharm.2022.109291_bib50","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1124\/dmd.105.005488","article-title":"Human CYP2D6 and mouse CYP2Ds: organ distribution in a humanized mouse model","volume":"33","author":"Miksys","year":"2005","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.neuropharm.2022.109291_bib27","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1046\/j.1471-4159.2002.01069.x","article-title":"Regional and cellular expression of CYP2D6 in human brain: higher levels in alcoholics","volume":"82","author":"Miksys","year":"2002","journal-title":"J. Neurochem."},{"key":"10.1016\/j.neuropharm.2022.109291_bib28","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1080\/004982500406390","article-title":"Regional and cellular distribution of CYP2D subfamily members in rat brain","volume":"30","author":"Miksys","year":"2000","journal-title":"Xenobiotica"},{"key":"10.1016\/j.neuropharm.2022.109291_bib29","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.pnpbp.2017.04.030","article-title":"Rat brain CYP2D enzymatic metabolism alters acute and chronic haloperidol side-effects by different mechanisms","volume":"78","author":"Miksys","year":"2017","journal-title":"Prog. Neuro-Psychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.neuropharm.2022.109291_bib51","doi-asserted-by":"crossref","first-page":"3077","DOI":"10.1111\/bph.12652","article-title":"Ethanol self-administration and nicotine treatment increase brain levels of CYP2D in African green monkeys","volume":"171","author":"Miller","year":"2014","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.neuropharm.2022.109291_bib30","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1248\/bpb.24.988","article-title":"Inactivation of rat cytochrome P450 2D enzyme by a further metabolite of 4-hydroxypropranolol, the major and active metabolite of propranolol","volume":"24","author":"Narimatsu","year":"2001","journal-title":"Biol. Pharm. Bull."},{"key":"10.1016\/j.neuropharm.2022.109291_bib31","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1124\/jpet.113.207548","article-title":"In vivo activity of norhydrocodone: an active metabolite of hydrocodone","volume":"347","author":"Navani","year":"2013","journal-title":"J. Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.neuropharm.2022.109291_bib32","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1038\/clpt.1993.177","article-title":"CYP2D6 phenotype determines the metabolic conversion of hydrocodone to hydromorphone","volume":"54","author":"Otton","year":"1993","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.neuropharm.2022.109291_bib33","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1124\/jpet.105.094276","article-title":"Comparison of the antinociceptive response to morphine and morphine-like compounds in male and female Sprague-Dawley rats","volume":"316","author":"Peckham","year":"2006","journal-title":"J. Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.neuropharm.2022.109291_bib34","article-title":"The ARRIVE guidelines 2.0: updated guidelines for reporting animal research","volume":"4","author":"Percie du Sert","year":"2020","journal-title":"BMJ Open Sci"},{"key":"10.1016\/j.neuropharm.2022.109291_bib35","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1007\/s002280050220","article-title":"Relationship between plasma desipramine levels, CYP2D6 phenotype and clinical response to desipramine: a prospective study","volume":"51","author":"Spina","year":"1997","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"10.1016\/j.neuropharm.2022.109291_bib36","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.cca.2013.11.015","article-title":"Hydrocodone in postoperative personalized pain management: pro-drug or drug?","volume":"429","author":"Stauble","year":"2014","journal-title":"Clin. Chim. Acta"},{"key":"10.1016\/j.neuropharm.2022.109291_bib37","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1007\/s00213-021-05808-9","article-title":"The role of CYP2D in rat brain in methamphetamine-induced striatal dopamine and serotonin release and behavioral sensitization","volume":"238","author":"Stocco","year":"2021","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.neuropharm.2022.109291_bib38","doi-asserted-by":"crossref","first-page":"4608","DOI":"10.1007\/s12035-020-02050-w","article-title":"Human CYP2D6 in the brain is protective against harmine-induced neurotoxicity: evidence from humanized CYP2D6 transgenic mice","volume":"57","author":"Stocco","year":"2020","journal-title":"Mol. Neurobiol."},{"key":"10.1016\/j.neuropharm.2022.109291_bib39","first-page":"1146","article-title":"Identification of cytochrome P-450 isoforms responsible for cis-tramadol metabolism in human liver microsomes","volume":"29","author":"Subrahmanyam","year":"2001","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.neuropharm.2022.109291_bib40","series-title":"Key Substance Use and Mental Health Indicators in the United States: Results from the 2020 National Survey on Drug Use and Health HHS Publication No. PEP21-07-01-003","year":"2021"},{"key":"10.1016\/j.neuropharm.2022.109291_bib41","doi-asserted-by":"crossref","first-page":"2509","DOI":"10.1007\/s12035-020-01896-4","article-title":"Human CYP2D6 is functional in brain in vivo: evidence from humanized CYP2D6 transgenic mice","volume":"57","author":"Tolledo","year":"2020","journal-title":"Mol. Neurobiol."},{"key":"10.1016\/j.neuropharm.2022.109291_bib42","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.yrtph.2010.12.007","article-title":"Uniform assessment and ranking of opioid \u03bc receptor binding constants for selected opioid drugs","volume":"59","author":"Volpe","year":"2011","journal-title":"Regul. Toxicol. Pharmacol."},{"key":"10.1016\/j.neuropharm.2022.109291_bib43","doi-asserted-by":"crossref","first-page":"335","DOI":"10.3109\/00498254.2014.981609","article-title":"Regulation of cerebral CYP2D alters tramadol metabolism in the brain: interactions of tramadol with propranolol and nicotine","volume":"45","author":"Wang","year":"2015","journal-title":"Xenobiotica"},{"key":"10.1016\/j.neuropharm.2022.109291_bib44","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/S0024-3205(01)01133-X","article-title":"Hydromorphone-3-glucuronide: a more potent neuro-excitant than its structural analogue, morphine-3-glucuronide","volume":"69","author":"Wright","year":"2001","journal-title":"Life Sci."},{"key":"10.1016\/j.neuropharm.2022.109291_bib45","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.ejphar.2007.02.042","article-title":"Activation of supraspinal NMDA receptors by both D-serine alone or in combination with morphine leads to the potentiation of antinociception in tail-flick test of rats","volume":"565","author":"Yoshikawa","year":"2007","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2022.109291_bib46","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1139\/jpn.0808","article-title":"Chronic nicotine treatment induces rat CYP2D in the brain but not in the liver: an investigation of induction and time course","volume":"33","author":"Yue","year":"2008","journal-title":"J. Psychiatry Neurosci."},{"key":"10.1016\/j.neuropharm.2022.109291_bib47","doi-asserted-by":"crossref","first-page":"3129","DOI":"10.1016\/j.lfs.2004.06.008","article-title":"Identification and synthesis of norhydromorphone, and determination of antinociceptive activities in the rat formalin test","volume":"75","author":"Zheng","year":"2004","journal-title":"Life Sci."},{"key":"10.1016\/j.neuropharm.2022.109291_bib48","doi-asserted-by":"crossref","first-page":"1848","DOI":"10.1016\/j.bcp.2013.04.014","article-title":"First demonstration that brain CYP2D-mediated opiate metabolic activation alters analgesia in vivo","volume":"85","author":"Zhou","year":"2013","journal-title":"Biochem. Pharmacol."}],"container-title":["Neuropharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390822003501?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390822003501?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,21]],"date-time":"2025-09-21T07:19:49Z","timestamp":1758439189000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0028390822003501"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12]]},"references-count":52,"alternative-id":["S0028390822003501"],"URL":"https:\/\/doi.org\/10.1016\/j.neuropharm.2022.109291","relation":{},"ISSN":["0028-3908"],"issn-type":[{"value":"0028-3908","type":"print"}],"subject":[],"published":{"date-parts":[[2022,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"CYP2D in the brain impacts oral hydrocodone analgesia in vivo","name":"articletitle","label":"Article Title"},{"value":"Neuropharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neuropharm.2022.109291","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"109291"}}